Kornimate/medical-research-clean huggingface dataset:
the use of brazilian green propolis extract (epp-af) in patients affected by covid-19.

Conditions: Covid19

Summary: the covid-19 pandemic is of grave concern due its impact on human health and on the economy. propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, anti-oxidant properties, and various aspects of the sars-cov-2 infection mechanism are potential targets for propolis compounds. propolis components have inhibitory effects on the ace2, tmprss2 and pak1 signaling pathways; in addition, antiviral activity has been proven in vitro and in vivo. this is a pilot randomized study that aims to assess the impact of using brazilian green propolis extract against the deleterious effects of the new coronavirus.


Eligibility criteria:
inclusion criteria: * hospitalized patients; * positive rt-pcr for sars-cov-2; * 18 years and older. exclusion criteria: * pregnant women; * people with active cancer; * patients undergoing transplantation of solid organs or bone marrow or who use immunosuppressive medications; * hiv carriers; * allergy to propolis or any of its components; * bacterial infection at randomization; * sepsis or septic shock before randomization; * patients unable to use medication orally or via nasoenteral tube; * patients with severe chronic liver disease (child b or c); * patients with advanced heart failure;

Keywords: propolis covid19 sars-cov-2 anti-inflammatory
outreach-er: a dementia care intervention program

Conditions: Dementia

Summary: this is a feasibility/pilot, prospective cohort study to determine how to implement and refine outreach-er intervention for a larger clinical study. a key feature of outreach-er is to reach out to people living with dementia (plwd) and their families following an emergency room visit or hospitalization. the outcome of this study will help in the overall goal of studying the impact of outreach-er in a larger clinical study and focus on outcomes relevant to plwd and their care partners.


Eligibility criteria:
inclusion criteria: * plwd with a recent emergency department visit or admission at regions hospital * diagnosis of dementia based on international classification of diseases (icd) codes in the medical record * provides informed consent prior to participation * must be able to read and speak english * plwd living at home * age \>=18 years for plwd and their care partner exclusion criteria: * plwd living in a nursing home/long term care - assisted living facility * current involvement in another clinical research study/trial for care partners * plwd medical record number (mrn) on the healthpartners (hp) exclusion list
comparative and additive diagnostic performance of magnetic resonance elastography (mre) and corrected-t1 (ct1) for fibrosis and inflammation in nonalcoholic steatohepatitis (nash) using histology as reference

Conditions: Nonalcoholic Fatty Liver; Nonalcoholic Steatohepatitis; Liver Fibroses; Liver Inflammation

Summary: this pilot study will evaluate conventional and investigational mr imaging and spectroscopic sequences and collect data to help plan more definitive future studies.

this prospective pilot study evaluates the comparative and additive diagnostic performance of magnetic resonance elastography (mre) and corrected-t1 (ct1) for the detection and staging of fibrosis and inflammation in nonalcoholic steatohepatitis (nash), using histology as the reference standard.

Eligibility criteria:
inclusion criteria: * adult subjects of any gender and any ethnic group with known or suspected nash * subject is willing and able to complete required research procedures (screening/enrollment, clinical evaluation, safety procedures, and research mri exam), and is willing to allow the study team to review clinical data including but not limited to other clinical radiology reports and images and clinical or research biopsy results * subject has been fully informed and has personally signed and dated the written informed consent and health insurance portability and accountability act (hipaa) documents * subject has had or is expected to have a clinical or research biopsy within 150 days of the mr exam exclusion criteria: * va subject * \< 18 years of age * subject does not have a physician and does not wish to be contacted about possible incidental findings * mri contraindication(s) * subject knows that she is pregnant or states she is trying to become pregnant
study of the safety and efficacy of golimumab in chinese patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the purpose of this study is to evaluate the safety and efficacy of golimumab in chinese patients with ankylosing spondylitis

golimumab is a type of tumor necrosis factor (tnf) inhibitor. tnf is a naturally occurring substance in the body, and this substance may cause long-term inflammation. golimumab may help fight disease by blocking the activity of tnf in the body and reducing inflammation and pain. each patient who is allowed to join the study will be put into a group randomly, like flipping a coin. patients may get either golimumab or placebo (which looks like the drug being studied but has no active ingredients, for example a sugar pill). the chance that the patient will get golimumab is 1 to 1, so 50% chance to receive golimumab and 50% change to receive placebo. patients who do not have an improvement in total back pain and morning stiffness at the week 16 visit compared to when the patients entered the study, and are in group 1 (placebo group), will receive golimumab 50 mg every 4 weeks starting at week 16. if the patient is in group 2 (golimumab 50 mg), they will continue to receive golimumab every 4 weeks starting at week 16. if the patient is in group 1 and still receiving placebo injections, because there was improvement in total back pain at week 16, they will receive golimumab 50 mg every 4 weeks starting from week 24. if the patient is in group 2 (golimumab 50 mg) or are already receiving golimumab injections at week 24, they will continue to receive golimumab every 4 weeks. safety will be monitored throughout the study, including drawing blood and looking at laboratory tests, vital signs (eg, blood pressure), and the frequency and type of adverse events (side effects). the patient will be in the study approximately 56 weeks. patients will receive placebo or active compound (golimumab 50 mg subcutaneous injections) every four weeks until week 48.

Eligibility criteria:
inclusion criteria: - have a diagnosis of definite akylosing spondylitis for at least 3 months * have symptoms of active disease at screening and at baseline * no active infections exclusion criteria: * have other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy * have complete ankylosis of the spine * have a history of latent or active granulomatous infection * have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (iv) antibiotics for an infection within 2 months prior to first administration of study agent.

Keywords: ankylosing sponylitis, injection, golimumab, simponi
differences between long distance road runners and treadmill runners in achilles tendon structure

Conditions: Achilles Tendon Injury

Summary: this study will investigate the structure of the achilles tendon and functional tests in road runners compared to treadmill runners.

healthy runners (road and treadmill runners) who run regularly at least twice a week for half an hour, over 80% of the training on the treadmill or road, will be recruited for the study. all subjects will fill out a demographic questionnaire for personal details (age, sex, height, weight, past injuries, training). each participant will undergo functional tests in random order: 1. examination of the morphology of the achilles tendon - will be examined by ultrasound tissue characterized (utc) 2. balance test - y balance test 3. proprioception test - ameda device 4. muscle strength test - manual dynamometer for testing gastrocnemius muscle strength. 5. gastrocnemius muscle endurance test - single leg heel raise test until fatigue. a comparison will be made between the two study groups.

Eligibility criteria:
inclusion criteria: * run regularly at least twice a week for half an hour, * over 80% of the training on a treadmill or road exclusion criteria: * pain or injury to achilles tendon during the 6 months, preventing running for at least 3 days. * past achilles tendon surgeries, * sprained ankle in the last six months, * lower limb and back pain while running * participants who report running with minimalist shoes.

Keywords: achilles tendon running
muscle oxygen saturation and functional capacity in breast cancer survivors

Conditions: Breast Cancer Survivorship; Muscle Oxygenation; Near-infrared Spectroscopy; Exercise; Quality of Life; Functional Capacity; Hormonal Therapy

Summary: this cross-sectional observational study aims to assess muscle oxygen saturation (smo2) in the intercostal, quadriceps, and triceps surae muscles using near-infrared spectroscopy (nirs) during functional exercise tests in breast cancer survivors. participants will be grouped based on their previous cancer treatment: hormonal therapy only or hormonal therapy combined with chemotherapy. functional performance will be evaluated through the 6-minute walk test, 30-second sit-to-stand test, and a submaximal treadmill test. the study will analyze differences in muscle oxygenation and performance between groups and explore associations with other functional and clinical parameters.

this study focuses on evaluating muscle oxygen saturation and physical performance in women who have survived breast cancer. cancer treatments such as chemotherapy and hormonal therapy can lead to systemic effects, including muscular deconditioning, fatigue, and reduced cardiorespiratory capacity. near-infrared spectroscopy (nirs) offers a non-invasive means of assessing smo2 in real-time, providing insight into oxygen delivery and utilization during exercise. participants will undergo three functional tests: the 6-minute walk test, the 30-second sit-to-stand test, and a submaximal treadmill test. muscle oxygenation will be measured in three key muscle groups before, during, and after each task. additional outcomes include functional test performance, respiratory strength, pulmonary function, fatigue perception, and quality of life questionnaires. this study will explore whether prior cancer treatment protocols affect muscle oxygenation and physical function differently, and may inform future rehabilitation strategies tailored to breast cancer survivors.

Eligibility criteria:
inclusion criteria: * women aged 30 to 70 years * clinical history of breast cancer treatment (at least 6 months prior) * completed primary cancer treatment * ability to perform physical tests * signed informed consent exclusion criteria: * recurrence or metastasis * severe cardiopulmonary or musculoskeletal disease * neurological or cognitive limitations * ongoing oncological treatment
a post-market clinical evaluation of st. jude medical™ mr conditional icd system on patients undergoing magnetic resonance imaging

Conditions: ICD; Tachycardia

Summary: to assess the clinical performance of the st. jude medical™ mr conditional icd system in patients undergoing an elective thoracic mri scan.

this clinical investigation is a prospective, multicenter, asian study. the study was designed with two (2) parts, however only the 1st part was completed. for the 1st part, patients were enrolled with a sjm mr conditional icd system approved for thoracic scan with 1.5 tesla mri scanning machines. the 2nd part-meant to enroll patients for thoracic scans with 3 tesla mri scanning machines-was not completed.

Eligibility criteria:
inclusion criteria: 1. subject is pectorally implanted with st. jude medical™ mr conditional icd system for at least 60 days 2. subject is willing to undergo an elective mri scan without sedation note: antianxiety agents (e.g. minor tranquilizers, etc.) may be used as long as the patient can communicate with site personnel during the mri scan 3. subject's ventricular bipolar capture threshold is stable \< 2.5v @ 0.5ms 4. subject's ventricular sensing is measurable (patient has underlying rhythm \> 30bpm) and the sensing amplitude is stable \> 4mv 5. subject is able to provide informed consent for study participation (legal guardian or legally authorized representative is not acceptable) 6. subject is willing and able to comply with the prescribed follow-up tests and procedures 7. subject is not contraindicated for an mri scan (per the mri screening form) exclusion criteria: 1. subject is pacemaker dependent 2. subject has a non sjm mri compatible endocardial lead implanted or capped 3. subject has another existing active implanted medical device, e.g., neurostimulator, infusion pump, etc. that has mr labeling that will not allow the mri scans per this protocol to be completed. 4. subject has a high voltage lead revision incidence \< 60 days of the enrollment visit 5. subject has other non-mri compatible device or material implanted note: mri compatible knee replacements, hip replacements, stents, etc. may be included as long as the labeling of these devices allow mri scans conducted per this protocol note: mri compatible mechanical, prosthetic, and bioprosthetic heart valves may be included as long as the labeling of these devices allow for mri scans conducted per this protocol note: non-removable dental implants may be included 6. subject has a lead extender, adaptor, or capped/abandoned lead 7. subject is enrolled or intend to participate in a clinical drug and/or device study (investigational device, investigational drug, new indication for a device or drug or additional testing beyond standard of care procedures), which could confound the results of this trial as determined by sjm. 8. subject is pregnant or planning to become pregnant during the duration of the subject's participation in the study 9. subject has a life expectancy of less than 12 months due to any condition 10. subject has exclusion criteria required by local law (e.g., age)

Keywords: icd thoracic mri scan tachycardia
the effect of pharmacist intervention on blood pressure control

Conditions: Hypertension

Summary: the purpose of the study is to test if a pharmacist intervention program with home blood pressure monitoring (hbpm) improves or controls pharmacological adherence and blood pressure levels in hypertensive patients under pharmacological treatment, compared to those who receive usual care in a community pharmacy setting.

hypertension is a major health concern worldwide due to its deleterious impact on the population in terms of excessive morbidity and mortality, especially when there is insufficient hypertension control and prevention at the community level.

Eligibility criteria:
inclusion criteria: * patients of both genders between the ages of 18 and 80 years, who access the pharmacy to fill their own prescription for hypertension. exclusion criteria: * patient living with an other hypertensive patient treated with the same medications * pregnant women * hypertensive patients with levels of systolic/diastolic blood pressure ≥ 180mmhg/110mmhg * patient with secondary hypertension, kidney or liver failure * patients already included in a care program for hypertensive patients * patients with a new treatment for hypertension (less than 1 month)

Keywords: home blood pressure measurement pharmaceutical services medication adherence hypertension management blood pressure
a rollover study of alectinib in patients with anaplastic lymphoma kinase (alk)-positive or rearranged during transfection (ret)-positive cancer

Conditions: Neoplasms

Summary: the purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with alk- or ret positive cancer who were previously enrolled in any roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.


Eligibility criteria:
inclusion criteria: * participants enrolled in a roche-sponsored alectinib trial who are experiencing a clinical benefit from alectinib or crizotinib treatment at the time of discontinuation from the parent trial and for whom a switch to commercial supply is not feasible * collected study termination data, including efficacy and safety data, as required by the parent study on the electronic case report form (ecrf) * for women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the last dose of study drug * for men: agreement to remain abstinent or use a contraceptive method that results in a failure rate of \< 1% per year during the treatment period and for at least 3 months after the last dose of study drug. exclusion criteria: * evidence of lack of clinical benefit in parent trial during the screening phase of this rollover study * permanent discontinuation of alectinib or crizotinib for any reason during the parent study or before first dose of study drug in the rollover study * evidence of an adverse event for which the parent protocol stipulates permanent discontinuation * pregnant or breastfeeding women * ongoing serious adverse event that has not resolved to baseline level or grade ≤1 prior to first dose of study treatment in the rollover study * treatment interruption for more than 21 days due to an adverse event since the last administration of alectinib or crizotinib in the parent trial. any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator * administration of strong/potent cytochrome p450 (cyp) 3a inhibitors or inducers within 14 days prior to the first dose of treatment on this study and while on treatment with crizotinib * any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; these conditions should be discussed with the participant before trial entry

Keywords: non-small cell lung cancer (nsclc) anaplastic lymphoma kinase (alk) rearranged during transfection (ret) alectinib crizotinib
study of axicabtagene ciloleucel versus standard of care therapy in participants with relapsed/refractory follicular lymphoma

Conditions: Relapsed/Refractory Follicular Lymphoma

Summary: the goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate long-term follow-up study (study kt-us-982-5968) to complete the remainder of the 15-year follow-up assessments.

Eligibility criteria:
key inclusion criteria: * histologically-confirmed follicular lymphoma (fl) (grade 1, 2, or 3a) * relapsed/refractory (r/r) disease after first-line chemoimmunotherapy and high-risk disease with relapse or progression within 24 months of the initial course of chemoimmunotherapy (ie, pod24), or r/r disease after ≥ 2 prior systemic lines of therapy * clinical indication for treatment. * at least 1 measurable lesion per the lugano classification {cheson 2014} * adequate renal, hepatic, pulmonary, and cardiac function key exclusion criteria: * presence of large b cell lymphoma or transformed fl * small lymphocytic lymphoma * lymphoplasmacytic lymphoma * full-thickness involvement of the gastric wall by lymphoma * fl grade 3b * prior cd19-targeted therapy * prior car therapy or other genetically modified t-cell therapy * uncontrolled fungal, bacterial, viral, or other infection * active infection with human immunodeficiency virus, hepatitis b virus or hepatitis c virus * history or presence of a clincially significant central nervous system (cns) disorder. * history of autoimmune disease * known history or cns lymphoma involvement * cardiac lymphoma involvement * history of clinically significant cardiac disease 6 months before randomization * neuropathy greater than grade 2 * females who are pregnant or breastfeeding * individuals of both genders who are not willing to practice birth control * presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling foley catheter, biliary drain, g/j-tube, pleural/peritoneal/pericardial catheter, or ommaya reservoirs). dedicated central venous access catheters such as port-a-cath or hickman catheter are permitted. note: other protocol defined inclusion/exclusion criteria may apply.
rh genotype matched rbc transfusions

Conditions: Sickle Cells Disease

Summary: to determine the feasibility and efficacy of matching donor red cells by rh genotype for a cohort of chronically transfused patients with scd.

this is a phase 1/2 trial in patients with sickle cell disease requiring chronic red cell transfusions. rh genotyped donor units will be obtained from the new york blood center. patients will be matched with donor units whose rh genotypes predict no foreign rh protein exposure to the patient. this will provide red cell matching at a level above the current standard of care (serologic c, e, and k matching). patients will receive rh matched red cells for the duration of their chronic transfusion therapy or up to three years, whichever is shorter. in the pilot phase, we have determined it is feasible to identify rh matched donor units for the patient's rh genotype for every scheduled transfusion. we will now continue to show feasibility as well as determine efficacy by monitoring rh alloantibody formation. for subjects with a history of stroke/recurrent transient ischemic attack or other indication who require tight control of hb s, and rh genotyped blood is not available, standard of care serologic matched blood would be administered rather than delaying transfusion and risking higher hb s level. for all subjects, standard of care serologic matched blood would be administered rather than delaying transfusion beyond 7 days.

Eligibility criteria:
inclusion criteria: * subjects age \>6 months * diagnosis of scd, all genotypes * require a period of chronic red cell transfusion therapy * subject/parental/guardian permission (informed consent) and if appropriate, child assent exclusion criteria: * rare rh genotype that would preclude identification of sufficient rbc units * antigen negative requirements due to alloimmunization that would preclude identification of sufficient rbc units * alloimmunized to d antigen * rh alloimmunized patients for whom providing rh genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols * parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures

Keywords: chronic transfusion